WO 2004/101546

CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

$$R^{1}$$
 $(R^{4})_{m}$
 $(R^{2})_{n}$
 (I)

5

10

15

25

35

wherein:

R¹ represents aryl, heteroaryl, -aryl-X-C₃₋₇ cycloalkyl, -heteroaryl-X-C₃₋₇ cycloalkyl, -aryl-X-aryl, -aryl-X-heteroaryl, -heteroaryl-X-heteroaryl, -heteroaryl-X-aryl or –heteroaryl-X-heterocyclyl;

wherein said aryl, heteroaryl and heterocyclyl groups of R¹ may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, haloC₁₋₈ alkyl, polyhaloC₁₋₈ alkyl, haloC₁₋₈ alkoxy, polyhaloC₁₋₈ alkoxy, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ alkoxy, -COC₁₋₈ alkyl, -

COC₁₋₆ alkyl-halogen, -COC₁₋₆ alkyl-cyano, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, C₁₋₆ alkylsulfonamidoC₁₋₈ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, aryl, arylsulfonyl, arylsulfonyloxy, aryloxy, arylsulfonamido, arylcarboxamido, aroyl, or a group NR¹⁵R¹⁶, -CONR¹⁵R¹⁶, -NR¹⁵COR¹⁶,

20 -C(R¹⁵)=NOR¹⁶, -NR¹⁵SO₂R¹⁶ or -SO₂NR¹⁵R¹⁶, wherein R¹⁵ and R¹⁶ independently represent hydrogen or C₁₋₆ alkyl or together form a heterocyclic ring;

X represents a bond, O, CO, SO₂, OCH₂ or CH₂O;

each R2 and R4 independently represents C1-4 alkyl;

 R^3 represents C_{3-8} alkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-6} cycloalkyl, C_{5-6} cycloalkyl; C_{3-6} cycloalkyl;

wherein said C_{3-6} cycloalkyl groups of R^3 may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, C_{1-4} alkyl or trifluoromethyl groups; m and n independently represent 0, 1 or 2;

30 p and q independently represent 1 or 2; or a pharmaceutically acceptable salt thereof.

2. A compound of formula (I) as defined in claim 1 wherein R¹ represents -aryl optionally substituted by 1, 2 or 3 halogen, C₁₋₆ alkyl, polyhaloC₁₋₆ alkyl, C₁₋₆ alkoxy, polyhaloC₁₋₆ alkoxy, -COC₁₋₆ alkyl, -C(R¹⁵)=NOR¹⁶, -NR¹⁵COR¹⁶, -COC₁₋₆ alkyl-halogen, -COC₁₋₆ alkyl-cyano, cyano or C₁₋₆ alkoxycarbonyl groups; -aryl-X-C₃₋₇ cycloalkyl;

-aryl-X-aryl;

5

15

20

30

35

40

- -aryl-X-heterocyclyl optionally substituted by 1, 2 or 3 halogen or oxo groups;
- -aryl-X-heteroaryl optionally substituted by a C₁₋₈ alkyl or aryl group;
- -heterocyclyl optionally substituted by 1, 2 or 3 C₁₋₆ alkyl or -COC₁₋₆ alkyl groups; heteroaryl optionally substituted by 1, 2 or 3 cyano, halogen, polyhaloC₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl or -CONR¹⁵R¹⁶ groups;
- -heteroaryl-X-aryl optionally substituted by 1, 2 or 3 cyano or $C_{\text{1-6}}$ alkylsulfonyl groups;
 - -heteroaryl-X-heterocyclyl; or
- 10 -heteroaryl-X-heteroaryl.
 - 3. A compound of formula (I) as defined in claim 2 wherein R¹ represents phenyl, naphthyl or indanone optionally substituted by 1, 2 or 3 halogen, C₁₋₈ alkyl, polyhaloC₁₋₈ alkyl, C₁₋₈ alkoxy, polyhaloC₁₋₈ alkoxy, -COC₁₋₈ alkyl, -C(R¹⁵)=NOR¹⁶, -NR¹⁵COR¹⁶, -COC₁₋₈ alkyl-halogen, -COC₁₋₈ alkyl-cyano, cyano or C₁₋₈ alkoxycarbonyl groups;
 - -phenyl-CO-cyclopropyl or -phenyl-CO-cyclobutyl;
 - —phenyl-thiazolyl, -phenyl-oxadiazolyl, -phenyl-pyrrolyl, —phenyl-oxazolyl or phenyl-isoxaxolyl optionally substituted by a C_{1-6} alkyl or aryl group; or
 - pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, quinolinyl, isoquinolinyl or benzothiazolyl optionally substituted by 1, 2 or 3 cyano, halogen, polyhalo C_{1-6} alkyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl or $-CONR^{15}R^{16}$ groups.
- 4. A compound of formula (I) as defined in claim 3 wherein R¹ represents phenyl optionally substituted by 1, 2 or 3 halogen, polyhaloC₁₋₆ alkyl, NR¹⁵COR¹6, -COC₁-6 alkyl or cyano groups;
 - -phenyl-CO-cyclopropyl;
 - -phenyl-oxadiazolyl or –phenyl-oxazolyl optionally substituted by a C_{1-8} alkyl or aryl group; or
 - pyridyl, pyrimidyl, pyrazinyl, pyridazinyl or quinolinyl optionally substituted by 1, 2 or 3 halogen, polyhalo C_{1-8} alkyl, C_{1-8} alkyl or cyano groups.
 - A compound of formula (I) as defined in claim 4 wherein R¹ represents
 phenyl optionally substituted at the 4-position by a -COMe, -COEt or cyano
 group; or
 - pyridyl or quinolinyl optionally substituted by a methyl or CF₃ group.
 - 6. A compound of formula (I) as defined in claim 5 wherein R¹ represents 6-CF₃-pyridin-3-yl.
 - 7. A compound of formula (I) as defined in any one of claims 1 to 6 wherein X represents a bond, O or CO.

8. A compound of formula (I) as defined in claim 7, wherein X represents a bond or CO.

- 5 9. A compound of formula (I) as defined in any one of claims 1 to 8 wherein m represents 0.
 - 10. A compound of formula (I) as defined in any one of claims 1 to 9 wherein n represents 0, 1 or 2.
 - 11. A compound of formula (I) as defined in claim 10 wherein n represents 0 or 1.

10

15

20

35

- 12. A compound of formula (I) as defined in claim 10 or claim 11 wherein ${\sf R}^2$ represents methyl.
- 13. A compound of formula (I) as defined in claim 11 wherein n represents 0.
- 14. A compound of formula (I) as defined in any one of claims 1 to 13 wherein q represents 1.
- 15. A compound of formula (I) as defined in any one of claims 1 to 14 wherein R^3 represents C_{3-8} alkyl or C_{3-6} cycloalkyl.
- 16. A compound of formula (I) as defined in claim 15 wherein R³ represents 25 isopropyl, isobutyl or cyclobutyl.
 - 17. A compound of formula (I) as defined in claim 16 wherein R³ represents isopropyl or cyclobutyl.
- 30 18. A compound of formula (I) as defined in claim 17 wherein R³ represents isopropyl.
 - 19. A compound of formula (I) as defined in claim 1 which is a compound of E1-E198 or a pharmaceutically acceptable salt thereof.
 - 20. A compound of formula (I) as defined in claim 1 which is 1-lsopropyl-4-[1-(5-cyano-pyridin-2-yl)-piperidine-4-carbonyl]-piperazine; 1-lsopropyl-4-[1-(5-methoxycarbonyl-4-trifluoromethylpyridin-2-yl)-piperidine-4-carbonyl]-piperazine;
- 40 1-Isopropyl-4-[1-(4-ethoxycarbonylphenyl)-piperidine-4-carbonyl]-piperazine; 1-Cyclobutyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-piperazine; 1-Cyclobutyl-4-[1-(4-cyano-3-fluorophenyl)-piperidine-4-carbonyl]-piperazine;

```
1-Cyclobutyl-4-[1-(4-cyano-2,6-difluorophenyl)-piperidine-4-carbonyl]-piperazine;
       1-Cyclobutyl-4-[1-(4-cyano-3-trifluoromethylphenyl)-piperidine-4-carbonyl]-piperazine;
       1-Cyclobutyl-4-[1-(4-cyano-naphthalen-1-yl)-piperidine-4-carbonyl]-piperazine;
       1-Cyclobutyl-4-[1-(5-cyanopyridin-2-yl)-piperidine-4-carbonyl]-piperazine;
       1-Cyclobutyl-4-[1-(6-trifluoromethylpyridin-2-yl)-piperidine-4-carbonyl]-piperazine;
       1-Cyclobutyl-4-[1-(5-trifluoromethylpyridin-2-yl)-piperidine-4-carbonyl]-piperazine;
       1-Cyclobutyl-4-[1-(3-chloro-5-trifluoromethylpyridin-2-yl)-piperidine-4-carbonyl]-
       piperazine;
       1-lsopropyl-4-{1-[5-(4-methylsulfonylphenyl)-pyrimidin-2-yl]-piperidine-4-carbonyl}-
10
      piperazine;
       1-Isopropyl-4-{1-[4-(morpholino-carbonyl)-phenyl]-piperidine-4-carbonyl}-piperazine;
       1-Cyclopentyl-4-[1-(4-cyano-phenyl)-piperidine-4-carbonyl]-piperazine;
       (2R,6S)-1-Cyclobutyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-2,6-
      dimethylpiperazine;
15
      1-Isopentyl-4-[1-(5-cyano-pyridin-2-yl)-piperidine-4-carbonyl]-piperazine;
      1-Cyclobutyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Cyclobutyl-4-[1-(5-cyanopyridin-2-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-lsopropyl-4-[1-(4-cyano-2,5-difluorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-lsopropyl-4-[1-(4-cyano-3-chlorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
20
      1-Isopropyl-4-[1-(4-cyano-3-fluoro-phenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Isopropyl-4-[1-(4-cyano-2,6-difluoro-phenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Isopropyl-4-[1-(4-cyano-2-fluoro-phenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Isopropyl-4-[1-(4-cyano-3-trifluoromethyl-phenyl)-piperidine-4-carbonyl]-[1,4]-
      diazepane;
25
      1-lsopropyl-4-[1-(4-trifluoromethyl-phenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Isopropyl-4-[1-(4-cyano-naphthalen-1-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Isopropyl-4-[1-(3,4-dichlorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Isopropyl-4-[1-(4-trifluoromethoxyphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-lsopropyl-4-[1-(4-difluoromethoxyphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Isopropyl-4-[1-(4-phenoxyphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
30
      1-lsopropyl-4-[1-(6-methoxypyridin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;1-
      Isopropyl-4-[1-(4-cyano-2,3-difluorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Isopropyl-4-[1-(4-cyano-2-chlorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Cyclobutyl-4-[1-(4-cyano-2-chlorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
35
      1-Cyclobutyl-4-[1-(4-cyano-3-chlorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Cyclobutyl-4-[1-(4-cyano-3-fluorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
      1-Cyclobutyl-4-[1-(4-cyano-3-trifluoromethylphenyl)-piperidine-4-carbonyl]-[1,4]-
      diazepane;
      1-Cyclobutyl-4-[1-(4-cyano-2,5-difluorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
40
      (S)-1-Isopropyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-2-methylpiperazine;
      (S)-1-Isopropyl-4-[1-(6-cyanopyridin-3-yl)-piperidine-4-carbonyl]-2-methyl piperazine;
```

(S)-1-Isopropyl-4-[1-(5-cyanopyridin-2-yl)-piperidine-4-carbonyl]-2-methyl piperazine;

(S)-1-Isopropyl-4-[1-(5-trifluoromethyl-pyrazin-2-yl)-piperidine-4-carbonyl]-2-methyl piperazine;

- (S)-1-Isopropyl-4-[1-(6-trifluoromethyl-pyridazin-3-yl)-piperidine-4-carbonyl]-2-methyl piperazine;
- 5 1-Isopropyl-4-{1-[4-(5-phenyl-1,3,4-oxadiazol-2-yl)phenyl]-piperidine-4-carbonyl} piperazine;
 - 1-Isopropyl-4-[1-(quinolin-6-yl)-piperidine-4-carbonyl] piperazine;
 - 1-Cyclobutyl-4-[1-(6-trifluoromethylpyridin-3-yl)-piperidine-4-carbonyl] piperazine;
 - 1-Isopropyl-4-[1-(5-trifluoromethyl-pyrazin-2-yl)-piperidine-4-carbonyl]-piperazine;
- 10 (S)-1-Isobutyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-piperazine;
 - 1-Isopropyl-4-[1-(4-cyclopropylcarbonylphenyl)-piperidine-4-carbonyl]-piperazine;
 - 1-Isopropyl-4-[1-(2-methyl-quinolin-6-yl)-piperidine-4-carbonyl]-piperazine;
 - 1-Isopropyl-4-[1-(6-cyano-pyridin-3-yl)-piperidine-4-carbonyl]-piperazine;
 - 1-Cyclobutyl-4-[1-(6-trifluoromethylpyridin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;
- 15 1-Cyclobutyl-4-[1-(2-cyanopyridin-4-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;
 - 1-Isopropyl-4-[1-(6-trifluoromethylpyridazin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;
 - 1-Isopropyl-4-[1-(5-trifluoromethylpyrazin-2-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;
 - 1-Isopropyl-4-{1-[4-(2-methyl-1,3-oxazol-5-yl)phenyl]-piperidine-4-carbonyl}-[1,4]-diazepane;
- 20 1-Isopropyl-4-{1-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-piperidine-4-carbonyl}-[1,4]-diazepane;
 - 1-Isopropyl-4-[1-(4-acetamido-3-fluorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
 - 1-Cyclobutyl-4-[1-(4-acetylphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
 - 1-Cyclobutyl-4-[1-(6-cyano-pyridin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;
- 25 1-Isopropyl-4-[1-(6-cyano-pyridin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;
 - 1-Isopropyl-4-[1-(2-methyl-quinolin-4-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;
 - 1-Isopropyl-4-{1-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-piperidine-4-carbonyl}-piperazine;
 - i-isopropyi-t-{ i-[4-(3-inetryi-1,2,4-0xadiazoi-5-yi)pinetryi]-pipetidiile-4-carbohyi]-pipetaziile
 - 1-Isopropyl-4-[1-(2-trifluoromethylpyrimidin-5-yl)-piperidine-4-carbonyl]-[1,4]-diazepane; or a pharmaceutically acceptable salt thereof.

30

- 21. A compound of formula (I) as defined in claim 1 which is
- 1-Isopropyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-piperazine;
- 1-lsopropyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
- (S)-1-Isopropyl-4-[1-(6-trifluoromethylpyridin-3-yl)-piperidine-4-carbonyl]-2-methyl
- 35 piperazine;
 - 1-lsopropyl-4-[1-(4-acetylphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
 - 1-lsopropyl-4-[1-(4-propanoylphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;
 - or a pharmaceutically acceptable salt thereof.
- 40 22. A compound of formula (I) as defined in claim 1 which is 1-lsopropyl-4-[1-(6-trifluoromethylpyridin-3-yl)-piperidine-4-carbonyl]-piperazine;
 - 1-Isopropyl-4-[1-(6-trifluoromethylpyridin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;

or a pharmaceutically acceptable salt thereof.

- 23. A pharmaceutical composition which comprises the compound of formula (I) as defined in any one of claims 1 to 22 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
- 24. A compound as defined in any one of claims 1 to 22 for use in therapy.
- 25. A compound as defined in any one of claims 1 to 22 for use in the treatment of neurological diseases.
 - 26. Use of a compound as defined in any one of claims 1 to 22 in the manufacture of a medicament for the treatment of neurological diseases.
- 15 27. A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in any one of claims 1 to 22 or a pharmaceutically acceptable salt thereof.
- 28. A pharmaceutical composition for use in the treatment of neurological diseases which comprises the compound of formula (I) as defined in any one of claims 1 to 22 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 29. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:
 - (a) reacting a compound of formula (II)

$$\begin{array}{c} \text{H-N} \\ \text{(R}^4)_{\text{m}} \\ \text{(II)} \end{array}$$

30

35

or an optionally activated or protected derivative thereof, wherein R^2 , R^4 , m, n, p and q are as defined in claim 1 and R^{3a} is as defined for R^3 in claim 1 or a group convertible to R^3 , with a compound of formula R^1 - L^1 , wherein R^1 is as defined in claim 1 and L^1 represents a suitable leaving group, such as a halogen atom followed by a deprotection reaction as necessary; or

15

(b) reacting a compound of formula (III)

wherein R¹, R⁴, m and q are as defined in claim 1 and L² represents OH or a suitable leaving group, such as a halogen atom, with a compound of formula (IV)

$$\begin{array}{c}
H \\
N \longrightarrow (R^2)_n \\
(N)_p \longrightarrow N \\
R^{3a}
\end{array}$$
(IV)

- wherein R², n and p are as defined in claim 1 R^{3a} is as defined for R³ in claim 1 or a group convertible to R³; or
 - (c) deprotecting a compound of formula (I) or converting groups which are protected; and optionally thereafter
 - (d) interconversion to other compounds of formula (i).